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Abstract 21 
Serial passage of viruses in cell culture has been traditionally used to attenuate virulence and 22 
identify determinants of viral pathogenesis. In a previous study, we found that a strain of 23 
Schmallenberg virus (SBV) serially passaged in tissue culture (termed SBVp32) unexpectedly 24 
displayed increased pathogenicity in suckling mice compared to wild type SBV. In this study, we 25 
mapped the determinants of SBVp32 virulence to the viral genome M segment. SBVp32 virulence is 26 
associated with the capacity of this virus to reach higher titers in the brains of experimentally 27 
infected suckling mice. We also found that the Gc glycoprotein, encoded by the M segment of 28 
SBVp32, facilitates host cell protein shutoff in vitro. Interestingly, while the M segment of SBVp32 is 29 
a virulence factor, we found that the S segment of the same virus confers by itself an attenuated 30 
phenotype to wild type SBV as has lost the ability to block the innate immune system of the host. 31 
Single mutations present in the Gc glycoprotein of SBVp32 are sufficient to compensate both the 32 
attenuated phenotype of the SBVp32 S segment and the attenuated phenotype of NSs deletion 33 
mutants. Our data also indicate that the SBVp32 M segment does not act as an IFN antagonist. 34 
Therefore SBV mutants can retain pathogenicity even when they are unable to fully control the 35 
production of IFN by the infected cells. Overall, this study suggests that the viral glycoprotein of 36 
orthobunyaviruses can compensate, at least in part, the function of NSs. In addition, we also provide 37 
evidence that the induction of total cellular protein shutoff by SBV is determined by multiple viral 38 
proteins while the ability to control the production of IFN maps to the NSs protein. 39 
Importance 40 
The identification of viral determinants of pathogenesis is key to the development of prophylactic 41 
and interventions measures. In this study we found that the bunyavirus Gc glycoprotein is a 42 
virulence factor. Importantly, we show that mutations in the Gc glycoprotein can restore 43 
pathogenicity of attenuated mutants resulting from deletions or mutations in the non-structural 44 
protein NSs. Our findings highlight the fact that careful consideration should be taken when 45 
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designing live attenuated vaccines based on deletions of non-structural proteins since single 46 
mutations in the viral glycoproteins appear to revert attenuated mutants to virulent phenotypes. 47 
48 
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Introduction 49 
The Bunyaviridae is one of the largest families of RNA viruses comprising pathogens of importance 50 
for both human and veterinary medicine. More than 170 viruses transmitted by arthropods form the 51 
Orthobunyavirus genus. Schmallenberg virus (SBV) is an orthobunyavirus of ruminants that emerged 52 
in central Europe in the summer of 2011 and spread very quickly throughout the rest of the 53 
continent (1). Although SBV genomes and antibodies have been detected in wild ruminants, 54 
camelids and a dog, so far only infections of ruminants have been associated with the disease (2-4). 55 
SBV has been detected in various Culicoides species and it is assumed that these insects provide the 56 
main route of transmission for this virus (5, 6).  57 
Infection of adult animals with SBV results in unspecific and mild clinical signs, while infection during 58 
gestation can result in stillbirths, abortions and malformations similar to infections with related 59 
viruses of the Simbu serogroup like Akabane virus (AKAV), Sathuperi virus (SATV) and Shamonda 60 
virus (SHAV) (7, 8). SBV was not detected in archived brain samples and no evidence of antibodies 61 
towards this virus was found in sera collected before 2010 in ruminants (9, 10). Hence, it is believed 62 
that the virus emerged for the first time in Europe in 2011. However, there is little information on 63 
the viral genetic characteristics and ecological conditions driving SBV emergence. 64 
Like other orthobunyaviruses, the SBV genome comprises three RNA segments of negative polarity 65 
referred to as small (S), medium (M) and large (L). The S segment encodes for the viral nucleocapsid 66 
and the non-structural protein NSs in an overlapping reading frame. The M segment encodes for the 67 
viral glycoproteins Gn and Gc, decorating the viral lipid bilayers, in addition to the NSm glycoprotein, 68 
a second non-structural protein of poorly defined characteristics. The L segment encodes for the 69 
viral RNA-dependent RNA polymerase (RdRp).  70 
Using reverse genetics, we and others have previously shown that the SBV NSs protein is a 71 
determinant of pathogenesis (11-13). Deletion of the SBV NSs protein results in attenuation of 72 
pathogenicity in a suckling mice model of infection. In vitro, NSs deletion (SBV-ΔNSs) leads to: i) 73 
impaired virus replication in interferon (IFN) competent cells; ii) inability to inhibit IFN synthesis in 74 
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infected cells; and iii) inability to induce cellular protein synthesis shutoff. The defects possessed by 75 
SBV-ΔNSs are the result, at least in part, of the incapacity of the mutated virus to induce the 76 
degradation/dephosphorylation of the cellular RNA polymerase II as means of inhibiting cellular 77 
transcription and the IFN response of the host (12). Regulatory authorities in some European 78 
countries have granted provisional marketing authorization for an inactivated SBV vaccine (14). In 79 
addition, a double NSs-NSm deletion SBV mutant has been proposed as a vaccine candidate as it 80 
provides full protection in cattle upon wild type virus challenge and does not induce viremia nor 81 
clinical signs in cattle (15).  82 
In an attempt to identify other viral determinants of pathogenicity, we serially passaged SBV in 83 
sheep IFN incompetent cells (CPT-Tert) and the resulting virus, referred to as SBVp32, was 84 
unexpectedly more virulent in 3 and 7 day-old NIH-Swiss mice inoculated intracerebrally (11). 85 
Although SBVp32 displayed similar replication kinetics to wild type SBV in CPT-Tert cells, it spread 86 
and induced pathological changes faster in the brains of suckling mice. We found SBVp32 to possess 87 
nucleotide substitutions (most of which non-synonymous) in all the viral genes compared to wild 88 
type SBV (11). The objective of this study was to identify the viral proteins associated with increased 89 
virulence of SBVp32 in order to better understand orthobunyavirus pathogenesis. We found that the 90 
Gc glycoprotein of SBVp32 is a virulence determinant and facilitates cellular protein synthesis 91 
shutoff. In addition, the SBVp32 Gc can compensate the attenuated phenotype of NSs deletion 92 
mutants. 93 
  94 
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Materials and Methods 95 
Cell lines. BSR-T7/5 cells (kindly provided by Karl Conzelmann) stably expressing the T7 polymerase 96 
were grown in Glasgow modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS), 97 
10% tryptose phosphate broth and G418 at a final concentration of 1 mg/ml. Sheep choroid plexus 98 
cells (CPT-Tert) (16) were grown in Iscove’s modified Dulbecco’s medium (IMDM) supplemented 99 
with 10% FBS. A549-ISRE-GFP expressing GFP under the control of an ISRE promoter (provided by R. 100 
Randall) (17) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 101 
FBS. All cell lines were cultured at 37°C in a 5% CO2 and 95% humidified atmosphere and were 102 
supplemented with penicillin and streptomycin.  103 
Isolation of primary fibroblasts. Ovine fibroblasts were isolated from sheep ear skin. Briefly, the 104 
dermal layer was removed, cut into explants and plated into dry tissue culture plates, dermis side 105 
up. The explants were incubated without media for 1 hour and then DMEM culture media containing 106 
10% FBS, penicillin and streptomycin and 1% nystatin was added. After sufficient outgrowth, the 107 
explants were discarded and the remaining cells cultured using standard methods. 108 
Antibodies. Antisera used in this study included a rabbit polyclonal antiserum against the SBV N 109 
protein (Proteintech) (11). Antibodies against γ tubulin were obtained from Sigma while antibodies 110 
against puromycin from Millipore (used at 1:3,000 dilution). Peroxidase labelled secondary 111 
antibodies against rabbit and mouse were purchased from GE Healthcare Life Sciences and Cell 112 
Signalling respectively.  113 
Viruses. All viruses used in this study were rescued by reverse genetics in BSR-T7/5 cells as 114 
previously described (11). Titers were determined by standard plaque assays performed in CPT-Tert 115 
cells. The reassortants derived in this study were named by including the segment corresponding to 116 
the SBVp32 strain. For example SBV-S32 contains the S segment from SBVp32 and the L and M 117 
segments from wild type SBV. SBVp32 refers to SBV passaged 32 times in cell culture. SBV-SML32 118 
contains all the segments from SBVp32 but was derived by reverse genetics. A deletion mutant of 119 
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the NSm protein was constructed by mutagenesis of the SBV M segment by deletion of amino acid 120 
residues 338 to 448 (Shi et al. unpublished results).  121 
Labelling of nascent proteins with puromycin. Monolayers of CPT-Tert cells at 30-40% confluency 122 
were infected with the indicated viruses at a multiplicity of infection (MOI) of 1.  16 hr post infection, 123 
the media was replaced with IMDM supplemented with 10ug/ml puromycin dihydrochloride (Sigma) 124 
for 12 min. Cells were then washed with PBS and lysed using 1x Laemmli buffer. SDS-PAGE and 125 
western blotting were performed from total cell lysates as previously described (18). For 126 
quantitative western blotting, primary antibodies were detected using peroxidase labelled 127 
secondary antibodies using a ChemiDoc XRS+ scanner and quantified with Image LabTM software 128 
(Biorad). γ-tubulin was used to normalize loading. All experiments were performed independently at 129 
least three times. For each virus, at least two independent virus preparations were used.  130 
Virus replication assays. Virus replication kinetics were determined by infection of the indicated cell 131 
lines at a multiplicity of infection (MOI) of 0.001, unless stated otherwise, followed by titration of 132 
supernatants collected at different time points post infection by limiting dilution assays in BSR cells. 133 
Titers are expressed as the tissue culture infectious dose 50 (TCID50; determined by the Reed-134 
Muench method). Each experiment was performed in triplicate and repeated three times using two 135 
different virus preparations. 136 
Immunofluorescence and confocal microscopy. The indicated cell lines were infected with the 137 
indicated viruses and fixed with 5% formaldehyde followed by immunofluorescence using a 138 
polyclonal antiserum towards the SBV N protein as previously described (19, 20). Slides were 139 
analysed by using a Leica GMIR2 confocal microscope. 140 
IFN bioassays. Primary sheep fibroblasts were infected with the indicated reassortants (MOI 1 or 141 
0.5) and 16 h post infection the supernatants collected and clarified. UV-inactivated supernatants 142 
were used to stimulate A549-ISRE-GFP for 24 hs when cells were fixed and the number of GFP 143 
positive cells was determined by FACS. The amount of IFN present in each sample was estimated 144 
based on an IFN standard of known concentration and expressed relative to SBV-ΔNSs. 145 
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Quantification of viral mRNA. Viral RNA was reverse transcribed using a SBV specific primer (5’- 146 
TTCGGCCCCAGGTGCAAATC-3’) with AccuScript HF reverse transcriptase following manufacturer’s 147 
instructions using 200 µg of total RNA. Two µl of cDNA were used for qRT-PCR using the Brilliant III 148 
Ultra Fast QPCR master mix as suggested by the manufacturer. Primers and probe used are the 149 
following: SBV-S-FW (TCAGATTGTCATGCCCCTTGC); SBV-S-RW (TTCGGC CCCAGG TGCAAATC); and 150 
SBV-S-FAM (TTAAGGGATGCACCTGGGCCGATGGC). Reactions were cycled on a Stratagene Mx3005 151 
qPCR System (Agilent Technologies) and data was analysed with the Mx3000P software.  152 
Histopathology and In situ hybridization. Organ samples were fixed in formalin and embedded in 153 
paraffin using standard histological techniques. Slides were stained with hematoxylin eosin (HE). 154 
In situ hybridization (ISH) to detect SBV mRNA was performed on all sections as described before 155 
(21). Briefly, paraffin sections were dewaxed, hydrated, and washed in DEPC-treated water. After 156 
proteolytic digestion, postfixation, acetylation, and prehybridization, sections were hybridized 157 
overnight with a digoxigenin-labeled probe (88 base pairs, 100 ng/ml) directed against the SBV 158 
nucleoprotein (21). Hybridized probes were detected using an anti-DIG antibody conjugated with 159 
alkaline phosphatase and the substrates nitrobluetetrazoliumchloride (NBT) and 5-bromo-4-chloro-160 
3-indolyl phosphate (BCIP, X-phosphate). SBV-positive and negative animals, as well as sections 161 
incubated only with hybridization buffer were included as controls. 162 
In vivo experiments. Animal experiments were carried out at the Istituto Zooprofilattico 163 
Sperimentale dell'Abruzzo e del Molise G. Caporale (Teramo, Italy) in accordance with locally and 164 
nationally approved protocols regulating animal experimental use (Protocol number 5383/2012). For 165 
survival studies, suckling NIH-Swiss mice (n=10-15 per each group) were inoculated intracerebrally 166 
with 400 PFU of the indicated reassortants/mutants and monitored daily for signs of disease for a 167 
period of 14 days. In order to test virus spread in the brain, 5 day old NIH-Swiss mice (n=3 per virus 168 
and timepoint) were inoculated intracranially with SBV, SBV-SML32 and SBV-M32 and euthanized at 169 
8, 24, 48 and 72h post-infection.  SBV and SBVp32 pathogenicity was also compared in adult IFNAR(-/-170 
) mice where groups of 5 mice were inoculated intraperitoneally (1,000 PFU) and the weight 171 
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recorded over a 15-day period. For histology and ISH, IFNAR(-/-) mice (n=2 per virus) were infected 172 
with either SBV, SBVp32 or uninfected cell culture media and animals were euthanized 3 days post-173 
infection. Organs were then collected for histological examination and ISH. 174 
Statistical analysis. Statistical analysis was performed using GraphPad Prism. All graphs display data 175 
average and standard deviations.  176 
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Results 177 
The M segment is a major determinant of SBVp32 virulence. Our first goal was to identify the viral 178 
genomic segment/s conferring higher virulence to SBVp32. To this end, we rescued by reverse 179 
genetics SBV, SBVp32 and the reassortants between the two viruses mentioned below as previously 180 
described (Fig. 1A) (11).  Table 1 shows the mutations present in the viruses used in this study.  181 
We inoculated 11-day old NIH-Swiss mice intracerebrally (400 PFU) with all the reassortants and 182 
survival was monitored for 15 days. All the reassortants carrying the M segment of SBVp32 were 183 
more pathogenic than wild type SBV (P ≤ 0.01 for SBV-SML32 and P ≤ 0.0001 for SBV-M32, SBV-184 
SM32 and SBM-SL32). These data suggest that the pathogenicity of SBVp32 maps to the M segment. 185 
A reassortant carrying the L segment of SBVp32 (SBV-L32) displayed the same pathogenicity of wild 186 
type SBV, however somewhat surprisingly a reassortant carrying the S segment of SBVp32 (SBV-S32) 187 
was attenuated (Fig. 1B). It is interesting to note that the attenuation conferred by the S segment of 188 
SBVp32 could be compensated by the M segment of SBVp32, since a SBV-SM32 mutant was more 189 
pathogenic than wild type (P ≤ 0.0001). 190 
We previously showed that SBVp32 spreads faster in the brains of infected mice (11). To understand 191 
the possible mechanisms behind the extra pathogenicity conferred by the M segment of SBVp32 we 192 
compared the amount of virus found in brains of 6-day old NIH-Swiss mice infected intracranially 193 
with wild type SBV, SBV-SML32 and SBV-M32. For each virus, groups of 3 mice were killed at 194 
different times post infection (8, 24, 48 and 72h) and total RNA was extracted from brains followed 195 
by qRT-PCR to quantify the number of SBV genome equivalents. We found that both SBV-SML32 and 196 
SBV-M32 reached higher number of viral genomes compared to wild type SBV in the brains of 197 
infected mice (Fig. 2) 198 
SBV-S32 attenuation maps to a single nucleotide change within the S segment. We first 199 
investigated the molecular determinants of the SBV-S32 attenuated phenotype. We derived 4 single 200 
mutant viruses (SBV-S-C66T, SBV-S-G124A, SBV-S-A167G and SBV-S-A319G) where nucleotides in 201 
positions 66, 124, 167 or 319 of the SBV S segment were mutated with the corresponding nucleotide 202 
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found in SBVp32 while the M and L segments were identical to SBV wild type. These mutants were 203 
used to inoculate suckling mice. All the mutants killed 100% of mice similarly to wild type SBV except 204 
for mutant SBV-S-A167G (carrying a G to A mutation corresponding to nucleotide 167 of the viral 205 
nucleocapsid gene and nucleotide 142 of the NSs gene) that was markedly attenuated (P ≤ 0.05; 206 
Fig.3A-B). 207 
 While all the reassortants had similar replication kinetics as wild type SBV in IFN incompetent cells 208 
(CPT-Tert cells), replication of SBV-S-A167G mutant was impaired in IFN competent primary sheep 209 
fibroblasts (Fig. 3C). This data suggests that the attenuation of the S segment of SBVp32 due to 210 
mutation at position 167/142 (N/NSs) relates to the inability of this virus to inhibit the production of 211 
IFN. To confirm these data we measured the ability of each mutant to induce IFN synthesis using an 212 
IFN bioassay. Primary sheep fibroblasts were infected with the different mutants, supernatants 213 
collected 16h post infection and the amount of IFN present was estimated as described in Materials 214 
and Methods. As expected no IFN was produced by cells infected with wild type SBV, while cells 215 
infected with SBV-S32 and SBV-S-A167G induced the release of IFN into supernatants (Fig. 4A).  216 
We have previously shown that the NSs protein of SBV counteracts the antiviral response of the host 217 
by inducing shutoff of host cell protein synthesis in line with other orthobunyaviruses (11-13, 22). To 218 
test if the attenuation of SBV-S32 relates to its inability to block cellular protein synthesis, we 219 
labelled nascent protein synthesis with puromycin in cells infected with the mutants described 220 
above and compared them by western blotting. Cells infected with SBV-∆NSs were used as control. 221 
SBV, SBV-S-C66T, SBV-S-G124A and SBV-S-A319G induced host cell proteins shutoff as expected. On 222 
the other hand, we found that SBV-S32 and SBV-S32-A167G were unable to induce total cellular 223 
protein shutoff similarly to SBV lacking the NSs protein (SBV-ΔNSs) (Fig. 4B).   224 
The M segment of SBVpP32 facilitates virus-induced shutoff of host cell protein synthesis. The 225 
results obtained so far indicated that SBVp32 is more virulent than wild type SBV even though it 226 
harbours a defective S segment that is unable to counteract the IFN response of the host cell. 227 
However, the defect of the S segment can be compensated, at least in the experimental mouse 228 
 12 | P a g e  
 
model used in our studies, by the M segment of SBVp32. Hence, we measured the ability of 229 
reassortants carrying the S segment of SBVp32 in combination with L and M segments of SBVp32 to 230 
shutoff protein synthesis by puromycin labelling of nascent proteins. These experiments were 231 
designed in order to understand whether the M segment of SBVp32 compensates the relative 232 
inability of the SBVp32 S segment to block cellular protein synthesis. As expected, all the controls 233 
used in the experiment worked as expected: SBV induced host protein shutoff while SBV-∆NSs or 234 
SBV-S32 were unable to do so (Fig. 5A). On the other hand, we found that any reassortant carrying 235 
the M segment of SBVp32 was able to induce global host protein shutoff, even in the presence of the 236 
attenuated S32 segment. In addition, SBV-L32 was also unable to block host protein synthesis, 237 
suggesting a role for the polymerase in this process. 238 
We then performed the same assays with reassortants deleted of the NSs protein in combination 239 
with the M or L segments of SBVp32 (SBV-SΔNSs-M32, SBV-SΔNSs-L32). We found that the M 240 
segment of SBVp32 was also able to compensate the defect in host protein shutoff displayed by a 241 
NSs deletion mutant (11) (Fig. 5B).  242 
The mutations that accumulated in the M segment of SBVp32 during serial passage map to both the 243 
NSm and the Gc glycoproteins (Fig. 6A and Table 1). To understand if the increased pathogenicity of 244 
SBVp32 maps to the NSm or the Gc glycoproteins, we mutated the NSm nucleotides within the SBV-245 
M32 backbone into those present in wild type SBV and tested the pathogenicity of the resulting 246 
reassortant in our mouse model of infection. We found that a virus carrying a wild type NSm protein 247 
and a SBVp32 Gc protein in combination with L and S segments from wild type SBV (SBV-Gc32-248 
NSmWT) was more pathogenic than wild type SBV in suckling mice (P≤ 0.001; Fig. 6B). In addition, 249 
the same reassortant in the context of a SBV S segment deleted of its NSs protein was still more 250 
pathogenic (SBV-SΔNSs-Gc32-NSmWT) than SBV wild type (P≤0.001).  251 
Next, we checked the ability of these mutants to induce total cellular protein shutoff using 252 
puromycin labelling of nascent proteins. As expected, we found that all the reassortants carrying the 253 
Gc glycoprotein of SBVp32 induced total cellular shutoff even in combination with impaired S 254 
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segments (S32 and SΔNSs) (Fig. 6C). In addition, complete deletion of the NSm protein did not affect 255 
the ability of the Gc SBVp32 glycoprotein to shutoff total cellular protein production nor restore the 256 
impaired cellular protein shut down capability of NSs mutants (SBV-S32-Gc32-ΔNSm and SBV-ΔNSs-257 
Gc32-ΔNSm) (Fig. 6D). 258 
Next, we introduced the individual non-synonymous nucleotide changes identified in the Gc gene of 259 
SBVp32 by site directed mutagenesis into SBV and rescued each mutant within the context of a SBV 260 
wild type L segment and the S segment of SBVp32. The resulting mutants were called SBV-S32-261 
MT1502C, SBV-S32-MA1894G, SBV-S32-MC2011G, SBV-S32-MA2236G, SBV-S32-MC2411T and SBV-262 
S32-MT2506C). Unfortunately, SBV-S32-G2575A could not be successfully rescued despite several 263 
attempts. We then assessed the capacity of each mutant to shutoff total cellular protein production. 264 
We found that mutations at positions 1894, 2236 and 2411 were individually capable of rescuing the 265 
defect of the S segment of SBVp32 (Fig. 6E).  266 
The M segment of SBVp32 is not an IFN antagonist. Next, we investigated if the M segment of 267 
SBVp32 could compensate the inability of the attenuated S32 segment to inhibit the production of 268 
IFN. To this end we firstly monitored the replication kinetics of a various SBVp32-SBV wild type 269 
reassortants in sheep IFN competent cells. We found that all reassortants carrying the S segment of 270 
SBVp32 (including those carrying M32) reached lower titers than wild type SBV (Fig. 7A). These data 271 
suggest that the S segment of SBV is by itself the major virus IFN-antagonist.  272 
To support these results we measured the ability of each reassortant to block the synthesis of IFN in 273 
infected cells as described above. We found that all the reassortants carrying the S segment of 274 
SBVp32 induced the release of IFN from infected cells, even when in combination with the M 275 
segment of SBVp32, although at lower levels compared to an NSs deletion mutant (Fig. 7B). These 276 
data indicate that for SBV, pathogenicity does not totally depend on the capability of the virus to 277 
inhibit the production of IFN but rather on its ability to induce total cellular protein shutoff. In 278 
addition, the data also suggest that virus induced global protein shutoff is not necessarily sufficient 279 
to block the production of IFN of the host.  280 
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The glycoprotein of SBVp32 facilitates early events of virus infection. The majority of the amino 281 
acid substitutions between wild type and SBV-M32 map to the Gc glycoprotein. Therefore, we 282 
reasoned that during serial passage in tissue culture the SBV glycoprotein evolved to reach a 283 
conformation to allow better entry. To test this hypothesis, we infected CPT-Tert cells with the same 284 
number of genome equivalents of SBV, SBV-M32 and SBV-SML32 (all segments from SBVp32) and 285 
the number of infected foci was quantified 8 hours post infection after immune staining of the viral 286 
nucleocapsid protein. We found a higher number of SBV positive foci in wells infected with SBVp32 287 
and SBV-M32 than wild type SBV, indicating that the M segment of SBVp32 facilitates early events of 288 
SBV infection (Fig. 8).  289 
SBVp32 virulence is related to increased virus replication also in the absence of an intact IFN 290 
response. Data obtained so far indicate that SBVp32 virulence is determined by its M segment and in 291 
particular by its ability to shutoff host protein synthesis and facilitate virus replication. The results 292 
obtained in NIH-Swiss mice suggest that SBVp32 virulence is therefore not linked to its ability to 293 
block the IFN response of the host. In order to support this conclusion, we compared the 294 
pathogenicity of SBV and SBVp32 in adult IFNAR(-/-) mice. We inoculated three groups of IFNAR(-/-)  295 
with SBV, SBVp32 or uninfected cell culture media as control (n = 5 per group). All the animals 296 
survived the length of the experiment and both SBV and SBVp32 infected animals developed signs of 297 
disease. However, they were more pronounced in SBVp32 infected animals. In addition, SBVp32 298 
infected animals displayed a statistically significant (p<0.05) more pronounced loss in weight 299 
compared to mock-infected controls (Fig. 9A).  300 
Next, we analysed virus distribution in a variety of organs by in situ hybridization (ISH) in three 301 
groups of IFNAR(-/-) mice (n=2 per group) infected with either SBV, SBVp32 or uninfected cell culture 302 
media. Mice were euthanized 3 days post-infection and organs were then collected for histological 303 
examination and ISH (Fig. 9B). The liver and spleen of SBV infected animals were the only organs 304 
displaying histopathological changes consisting with mild to moderate inflammation. SBV mRNA was 305 
detected by in situ hybridization in both macrophages and hepatocytes in the liver and in 306 
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macrophages in the spleen.  SBV mRNA was also detected in the mandibular and mesenteric lymph 307 
nodes. On the other hand, moderate to severe necrosuppurative hepatitis, suppurative splenitis and 308 
lymphadenitis were found in samples derived from SBVp32 infected animals. These lesions were 309 
associated with the presence of moderate to high amounts of SBV mRNA in hepatocytes and 310 
macrophages. One animal showed non-suppurative interstitial nephritis that was associated with the 311 
presence of mild to moderate SBV mRNA. Degenerative and inflammatory lesions were identified in 312 
the heart while mild pathomorphological changes were present in the small intestine and the spinal 313 
cord but no SBV mRNA was detected in the latter. Table 2 displays the organs in which the presence 314 
of SBV mRNA was evaluated.     315 
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Discussion 316 
In this study we showed that a cell culture adapted strain of SBV (SBVp32) has a more virulent 317 
phenotype than its wild type parental strain due to amino acid substitutions in the Gc glycoprotein. 318 
Importantly, we show that SBVp32 virulence is increased by the capacity of the Gc to facilitate host 319 
protein shutoff and early events of virus replication, at least in the experimental models employed in 320 
this study. Surprisingly, SBVp32 is more virulent than wild type SBV but carries a defective S segment 321 
that is unable to inhibit the production of IFN and fails to induce total cellular protein shutoff in 322 
infected cells. This defect is however compensated in SBVp32 by Gc. Altogether our data indicate 323 
that the induction of total cellular protein shutoff in SBV is determined by multiple genes while the 324 
ability to inhibit the production of IFN maps mainly to the NSs protein. 325 
 The S segment of SBV encodes the nucleocapsid and the non-structural protein NSs in overlapping 326 
reading frames. We have previously shown that the SBV NSs protein is a virulence factor that inhibits 327 
the synthesis of IFN of infected cells and controls the innate immune system of the host by blocking 328 
cellular protein production (11, 12). Thus, it is not surprising that the S segment of SBVp32 lost the 329 
ability to repress the production of IFN given that it was serially passaged in CPT-Tert cells (sheep 330 
cells that don’t to produce IFN upon viral infection). The NSs protein of SBVp32 also showed a 331 
decreased ability to induce total cellular protein shutoff. These observations suggest that IFN 332 
antagonism and the capacity to induce total cellular protein shutoff by the NSs protein are linked 333 
and require an arginine residue at position 49. Residue 49 is part of a nucleolar localization signal. 334 
Thus the change from arginine to glycine in SBVp32 could likely be associated with a change in the 335 
cellular localization of NSs leading to its loss of function and evidenced as an attenuated phenotype 336 
in suckling mice. However, pathogenicity is restored and even enhanced in those reassortants that 337 
contain also the Gc glycoprotein of SBVp32. The SBVp32 Gc protein acquired the ability to induce 338 
total cellular protein shutoff during serial passage but cannot compensate the IFN antagonism of 339 
NSs. Altogether, these data suggest that the capacity to inhibit IFN production by SBV maps mainly 340 
to the NSs protein. On the other hand, SBV virulence is associated with the ability of the virus to 341 
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induce total cellular protein shutoff rather than IFN antagonism. This is further supported by the fact 342 
that SBVp32 induces more severe clinical signs in adult IFNAR(-/-)compared to wild type SBV. These 343 
data also indicates that the ability to block IFN and induce cellular protein shutoff by the NSs protein 344 
come with a “cost” for the virus that is easily disposed once no longer required. 345 
SBVp32 cannot fully inhibit the synthesis of IFN and its replication is impaired in IFN competent cells, 346 
however it is still more pathogenic than wild type SBV in suckling mice. A possible explanation for 347 
these contrasting observations is that in infections with viruses expressing the SBVp32 Gc protein, 348 
cellular shutoff precedes the induction of IFN thus quickly overcoming the upregulation of ISGs and 349 
leading to pathogenicity. We need to take into consideration that we quantified the amount of IFN 350 
released into the supernatant of infected cells early in infection (16 h post infection). It is possible 351 
that a different effect on IFN synthesis is seen at later time points during infection and more studies 352 
will be required to address this point. In addition, the IFN bioassays were performed in primary cell 353 
cultures derived from adult animals. We have previously shown, like for other viral infections (23, 354 
24), that there is an age-dependent resistance to SBV infection in suckling mice (11) that could be 355 
attributed to the development of anatomic barriers, the reticularendothelial system, the IFN and 356 
immune responses and thus the increased pathogenicity of SBVp32 could be due to many factors. It 357 
still remains to be determined if SBVp32 is more pathogenic also in ruminants and how this virus 358 
controls the innate immune system in its natural host. 359 
Deletion of the NSs protein in wild type SBV does not lead to a full recovery of protein expression in 360 
infected cells (Fig. 4B) indicating that other viral proteins are involved in inducing cellular protein 361 
shutoff. In addition, only eight serogroups encode NSs proteins among the viruses of the 15 362 
orthobunyavirus serogroups for which genomic data are available highlighting the fact that 363 
orthobunyaviruses use alternative mechanisms to cope with the innate immune system of the host 364 
(25, 26).  Here we observed that the L segment of SBV contributes to the induction of cellular 365 
protein shutoff given that a reassortant comprising M and S segments of wild type SBV and the L 366 
segment of SBVp32 (SBV-L32) was less capable of shutting down protein expression than wild type 367 
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SBV (Fig. 5A). Although we did not map the particular residues associated with this, we can speculate 368 
that mutation at position 130 could be involved since it sits within the endonuclease motif of the 369 
viral polymerase. The endonuclease activity of the bunyavirus polymerase allows a “cap-snatching 370 
mechanism” by which the viral polymerase cleaves the 5’ cap of cellular mRNAs to use as primers for 371 
viral mRNA transcription therefore reducing the cellular pools of mRNA for translation (27). We also 372 
found that the SBV NSm protein contributes to cellular protein shutoff (Fig. 4D). Interestingly, in 373 
another study complete deletion of the NSm coding region resulted in a virus that, within the 374 
context of a wild type M and L segments (SBV-ΔNSm) was unable to induce cellular protein shutoff 375 
but had no effect on the ability to control the production of IFN of infected cells (Elliott and Shi 376 
personal communication). This is in agreement with studies carried out on Bunyamwera virus 377 
(BUNV) where deletions of internal domains of NSm resulted in a similar phenotype, although a 378 
complete NSm deletion mutant could not be rescued by reverse genetics (28) suggesting that NSm 379 
might play different roles in different orthobunyaviruses.  Although BUNV NSm has been involved in 380 
playing a role in assembly and morphogenesis, its role in controlling the innate immunity of the host 381 
requires further investigation.   382 
The molecular mechanism of SBV Gc-induced protein shutoff remains to be determined. However 383 
given that the Gc glycoprotein of other orthobunyaviruses including SBV transit from the 384 
endoplasmic reticulum (ER) to the Golgi apparatus (29) (not shown) it can be expected that they 385 
trigger the ER stress response. Several viruses use this strategy to favour translation of viral proteins 386 
(30). Viral infection can quickly lead to excess protein and the accumulation of misfolded products in 387 
the ER which ultimately results in the phosphorylation of eIF2. eIF2 phosphorylation results in cap-388 
dependent protein synthesis shutoff reliving the burden of the accumulation of proteins in the ER 389 
and evidenced as a reduction in total cellular protein expression (31).  390 
Reassortants carrying the SBVp32 M segments reached higher virus titers in the brains of infected 391 
mice and were more infectious in vitro. We hypothesize that during serial virus passage and without 392 
pressure from neutralizing antibodies the Gc protein accumulated mutations that allow more 393 
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efficient entry and thus faster spread. However, it remains to be determined if this virus could be 394 
viable or if it could be more pathogenic in its natural hosts given the possibility that it could be 395 
better neutralized. It is possible that faster entry or higher replication conferred by the SBVp32 Gc 396 
glycoprotein allows earlier expression of other viral proteins (such as the viral polymerase and/or 397 
NSm), leading to faster induction of cellular protein shutoff compared to wild type virus. 398 
Unfortunately, we have not been able to express the viral glycoproteins to high levels using a 399 
transient transfection system to test the role of Gc in protein shutoff independently of other viral 400 
components. These data could be an indication that expression of Gc leads to protein synthesis 401 
shutoff resulting in repression of its own plasmid.  402 
We showed that single point mutations in Gc (1894, 2236 and 2411) rescue the inability of the S 403 
segment of SBVp32 to induce total cellular protein shutoff. There are currently less than ten SBV M 404 
segment sequences derived from field isolates, thus our understanding of the true genetic diversity 405 
of this virus and the consensus sequence circulating in affected countries is very limited. 406 
Interestingly, SBVp32 mutation at position 2236 exists in the field, indicating that it can lead to viable 407 
virus. Given that we found a consistent positive correlation between the ability of our reassortants 408 
to induce protein shutoff and be more pathogenic in our mouse model of infection we can conclude 409 
that a single amino acid change in the Gc glycoprotein can potentially rescue attenuated phenotypes 410 
based on mutations of the S segment. Importantly, we also showed that the defect in inducing host 411 
protein shutoff by a double NSs and NSm deletion mutant can be rescued by amino acid changes in 412 
the Gc glycoprotein and that at least one of the changes exists in viruses circulating in the field. 413 
Therefore live attenuated vaccines based on deletion of NSs and NSm require further careful 414 
consideration. 415 
416 
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Tables 420 
Table 1. Nucleotide differences between SBV wild type and SBVp32. 421 
Segment SBV nt SBV nt SBVp32 
nt 
syn/non-syn Location
 N NSs  N NSs N/NSs
S 
66 
 
41 C T Syn Non-syn N/NSs
124 99 G A Non-syn Syn N/NSs
167 142 A G Non-syn Non-syn N/NSs
319 n/a A G Non-syn n/a N
M 
1016 G A Non-syn NSm
1239 T G Non-syn NSm
1502 T C Non-syn Gc “hot spot”
1894 A G Non-syn Gc
2011 C G Syn Gc
2236 A G Non-syn Gc
2411 C T Non-syn Gc
2506 T C Non-syn Gc
2575 G A Non-syn Gc
L 
130 T C Non-syn Endonuclease region 
3044 T C Non-syn
3858 A G Non-syn
4078 C T Non-syn
 422 
  423 
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 424 
Table 2. Organs in which the presence of SBV mRNA was evaluated by in situ hybridization.  425 
 sSBV SBVp32 Controls 
 Mouse 1* Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mouse 6 
Salivary gland 0 0 + 0 0 0 
Mandibular lymph 
node 
+ 0 +++ +++++ 0 n.d. 
Pharynx 0 0 n.d. 0 0 0 
Thyroid gland 0 n.d. n.d. 0 n.d. 0 
Lungs 0 0 0 0 0 0 
Thymus 0 n.d. n.d. n.d. n.d. 0 
Heart 0 0 0 xx 0 0 
Liver +++ 0 ++++++ ++++++ 0 0 
Spleen +++++ 0 +++++ +++++ 0 0 
Kidney 0 0 +++ 0 0 0 
Testis 0 0 0 0 0 0 
Cerebellum 0 0 0 0 0 0 
Brain stem 0 0 0 0 0 0 
Cerebrum 0 0 0 0 0 0 
Stomach 0 0 0 0 0 0 
Small intestine 0 0 + ++ 0 0 
Large intestine 0 0 0 ++ 0 0 
Pancreas 0 0 0 0 0 0 
Mesenteric lymph 
node 
++ n.d. +++++ n.d. 0 0 
Spinal cord 0 0 0 0 0 0 
Bone marrow ++++ 0 +++++ +++++ 0 0 
 426 
*Mouse 1 to 6 indicate the individual animals. 0 no positive cells; x single positive cells; xx small 427 
number of positive cells; xxx   small to moderate number of positive cells; xxxx   moderate number of 428 
positive cells; xxxxx moderate to large number of positive cells; xxxxxx large number of positive cells. 429 
  430 
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Figure Legends 431 
Figure 1. SBVp32 pathogenicity maps to the M segment. A. Schematic representation of SBV 432 
reassortants generated by reverse genetics. B.  Survival plots of 11-day old NIH-Swiss mice 433 
inoculated intracerebrally with 400 PFU of the indicated reassortants. Survival of mice inoculated 434 
with wild type SBV has been included in each panel to facilitate comparisons. Asterisks indicate 435 
significance levels: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001 (Log-Rank test, Mantel Cox 436 
test).    437 
Figure 2. SBV carrying the M segment of SBVp32 reaches higher genome copy numbers in the 438 
brains of infected mice. Groups of 3 mice were infected intracranially and brains harvested at the 439 
indicated times post infection. Viral genome equivalents were quantified by qRT-PCR. Data was 440 
analysed using a 2-way ANOVA (top asterisks indicate the significance level between SBV and SBV-441 
SML32 while bottom asterisks between SBV and SBV-M32). 442 
Figure 3. SBV-S32 attenuation maps to nucleotide 167/142 of nucleocapsid/NSs gene. A. schematic 443 
representation displaying the position of nucleotide changes of SBVp32 compared to wild type SBV 444 
in the nucleocapsid and NSs open reading frames. Asterisks indicate non-synonymous changes. B. 445 
Survival plots of 7-day old mice inoculated intracerebrally with 400 PFU of the indicated 446 
reassortants. Asterisks indicate significance levels: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 447 
0.0001 (Log-Rank test, Mantel Cox test). C. Replication kinetics of SBV S point mutants in CPT-Tert 448 
and primary sheep fibroblasts. The graph displays the average of two and four independent 449 
experiments respectively.  450 
Figure 4. Mutation at nucleotide 167/142 of nucleocapsid/NSs gene of the S segment of SBVp32 451 
impairs the ability to induce total cellular protein shutoff and to control interferon production of 452 
infected cells. A. Interferon bioassay. Primary sheep fibroblasts were infected with the indicated 453 
reassortants (MOI 1) and the amount of IFN present in supernatants was estimated by comparing 454 
the ability to induce GFP expression in A549 cells stably expressing GFP under ISRE promoter to 455 
known quantities of universal IFN. Data is expressed relative to SBV-ΔNSs, known to induce IFN 456 
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synthesis. E. Western blots displaying puromycin labelled proteins 16 h after infection with the 457 
indicated reassortans (MOI 1). Infection with SBV-ΔNSs was used as control given its ability to shut 458 
down cellular protein synthesis. Γ-tubulin was used as a loading control and SBV N to confirm 459 
infection. The numbers indicate the quantification of each lane relative to mock that was set at 460 
100%. 461 
Figure 5. The M segment of SBVp32 rescues the inability of attenuated S segments to induce total 462 
cellular protein shutoff. Western blots displaying puromycin labelled proteins 16 h after infection 463 
with the indicated reassortans (MOI 1). γ-tubulin was used as a loading control and SBV N to confirm 464 
infection. The numbers indicate the quantification of each lane relative to mock that was set at 465 
100%. A. Reassortants carrying the S segment of SBVp32 in combination with wild type or SBVp32 M 466 
and L segments. B. Reassortants carrying a wild type SBV S segment deleted of its NSs protein in 467 
combination with wild type or SBVp32 M and L segments. 468 
Figure 6. SBVp32 pathogenicity maps to the Gc glycoprotein. A. Schematic representation of 469 
SBVp32 mutations within the M segment. B. Survival plots of 8-day old NIH-Swiss mice inoculated 470 
intracerebrally with 400 PFU of the indicated reassortants. Asterisks indicate significance levels ns 471 
p>0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001 (Log-Rank test, Mantel Cox test). C-D-472 
E. Western blots displaying puromycin labelled proteins 16 h after infection with the indicated 473 
reassortans (MOI 1). Γ-tubulin was used as a loading control and SBV N to confirm infection. The 474 
numbers indicate the quantification of each lane relative to mock that was set at 100%. 475 
Figure 7. Replication kinetics of SBVp32 reassortants in IFN competent cells. A. Primary sheep 476 
fibroblasts and were infected (MOI 0.001) with the indicated reassortants and samples collected at 477 
the indicated times post infection. The graph shows the average of four independent experiments. 478 
B. Interferon bioassay. Primary sheep fibroblasts were infected with the indicated reassortants (MOI 479 
0.5) and the amount of IFN present in supernatants was estimated as described in Fig.4.  480 
Figure 8. SBVp32 glycoprotein is more infectious than the wild type SBV glycoprotein. CPT-tert cells 481 
were infected with 2.5 105 genome equivalents of the indicated viruses and the number of SBV 482 
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positive cells was counted 8 hours post infection after immune staining. 10 view fields were counted 483 
for each condition. The percentage of positive cells is presented relative to wild type SBV infection. 484 
The experiment was repeated 3 times independently. Data was analysed using ANOVA (p 0.0076). 485 
Figure 9. SBVp32 virulence is related to increased virus replication in IFNAR(-/-) knockout mice.  A. 486 
Groups of 5 mice were inoculated intraperitoneally (1,000 PFU) and the weight recorded over a 15-487 
day period. The area under the curve was estimated for each mouse and then compared among 488 
groups (ANOVA p<0.05, Tukey multiple comparison test). B. Representative micrographs displaying 489 
the pathological changes observed in SBVp32-infected IFNAR(-/-) knockout mice (left) and the 490 
presence of viral RNA by in situ hybridization (ISH) (right).   491 
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